BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1107 related articles for article (PubMed ID: 22613095)

  • 1. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
    Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
    Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
    Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
    Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype.
    Fortunati N; Marano F; Bandino A; Frairia R; Catalano MG; Boccuzzi G
    Int J Oncol; 2014 Mar; 44(3):700-8. PubMed ID: 24366407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
    Kubo M; Kanaya N; Petrossian K; Ye J; Warden C; Liu Z; Nishimura R; Osako T; Okido M; Shimada K; Takahashi M; Chu P; Yuan YC; Chen S
    Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
    Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
    Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.
    Liu H; Wang Y; Li X; Zhang YJ; Li J; Zheng YQ; Liu M; Song X; Li XR
    Tumour Biol; 2013 Jun; 34(3):1713-22. PubMed ID: 23430586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines.
    De Santi M; Galluzzi L; Lucarini S; Paoletti MF; Fraternale A; Duranti A; De Marco C; Fanelli M; Zaffaroni N; Brandi G; Magnani M
    Breast Cancer Res; 2011 Mar; 13(2):R33. PubMed ID: 21435243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
    Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
    Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
    Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A
    Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
    Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L
    Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
    Lin Z; Zhang Z; Jiang X; Kou X; Bao Y; Liu H; Sun F; Ling S; Qin N; Jiang L; Yang Y
    Oncotarget; 2017 Mar; 8(11):17833-17848. PubMed ID: 28147319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
    PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
    Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
    J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.
    Hahne JC; Schmidt H; Meyer SR; Engel JB; Dietl J; Honig A
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):905-14. PubMed ID: 23440492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
    LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
    Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
    Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
    Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.